Antibody-mediated encephalitis: A treatable cause of schizophrenia

British Journal of Psychiatry

Volumn 200, Issue 2, 2012, Pages 92-94

  Lennox, Belinda R ^a   Coles, Alasdair J ^b   Vincent, Angela ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; DISEASE COURSE; HUMAN; NEUROIMAGING; NEUROIMMUNOLOGY; REVIEW; SCHIZOPHRENIA; SEIZURE;

AUTOANTIBODIES; ENCEPHALITIS; FEMALE; HUMANS; POTASSIUM CHANNELS, VOLTAGE-GATED; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84857099397     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.111.095042     Document Type: Review

References (11)

1. Bullmore E, Fletcher P, Jones PB. Why psychiatry can't afford to be neurophobic. Br J Psychiatry 2009; 194: 293-5.
2. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36. (Pubitemid 46214241)
3. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655-67.
4. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld M, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
5. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-8.
6. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10: 759-72.
7. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004; 127: 701-12. (Pubitemid 38295483)
8. Parthasarathi UD, Harrower T, Tempest M, Hodges JR, Walsh C, McKenna PJ, et al. Psychiatric presentation of voltage-gated potassium channel antibody-associated encephalopathy. Case report. Br J Psychiatry 189: 182-3.
9. Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011; 258: 686-8.
10. Kraepelin E. Dementia Praecox and Paraphrenia (ed. G Robertson). Livingstone, 1919.
11. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, et al. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br J Psychiatry 2006; 189: 173-9. (Pubitemid 44231278)